{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:06:19Z","timestamp":1789016779065,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejpb.2025.114719","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:10:53Z","timestamp":1744492253000},"page":"114719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-0062","authenticated-orcid":false,"given":"Janis","family":"Niessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7558-8309","authenticated-orcid":false,"given":"Nathalie","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-9389","authenticated-orcid":false,"given":"Markus","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-0447","authenticated-orcid":false,"given":"Ilse R.","family":"Dubbelboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4355-739X","authenticated-orcid":false,"given":"Thomas","family":"Borchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1385-182X","authenticated-orcid":false,"given":"Mirko","family":"Koziolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-5184","authenticated-orcid":false,"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anura","family":"Indulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-2906","authenticated-orcid":false,"given":"David","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114719_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810328","article-title":"Recent Advances in PROTACs for Drug Targeted Protein Research","volume":"23","author":"Yao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2025.114719_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105848","article-title":"Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery","volume":"125","author":"Xi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0015","doi-asserted-by":"crossref","first-page":"14629","DOI":"10.1021\/ja508343a","article-title":"Privileged structures: Efficient chemical \u201cnavigators\u201d toward unexplored biologically relevant chemical spaces","volume":"136","author":"Kim","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2025.114719_b0020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114719_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ddtec.2019.02.005","article-title":"Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations","volume":"31","author":"Watt","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2025.114719_b0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbamcr.2013.06.031","article-title":"Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system","volume":"1843","author":"Amm","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2025.114719_b0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2025.114719_b0040","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted Protein Degradation: from Chemical Biology to Drug Discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejpb.2025.114719_b0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2025.114719_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.str.2015.10.020","article-title":"Structural Basis for the Non-catalytic Functions of Protein Kinases","volume":"24","author":"Kung","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.ejpb.2025.114719_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Advanced drug delivery reviews"},{"key":"10.1016\/j.ejpb.2025.114719_b0060","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0065","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs)in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2025.114719_b0070","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/acsomega.2c07717","article-title":"Predictive Modeling of PROTAC Cell Permeability with Machine Learning","volume":"8","author":"Poongavanam","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2025.114719_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080411","article-title":"Intestinal permeability and drug absorption: predictive experimental, computational and in vivo approaches","volume":"11","author":"Dahlgren","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114719_b0080","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and Physicochemical Features of Oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0085","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/acsmedchemlett.3c00231","article-title":"The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline","volume":"14","author":"Apprato","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2025.114719_b0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2025.114719_b0095","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","article-title":"Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)","volume":"61","author":"Powell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0100","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acs.jmedchem.8b01826","article-title":"Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions","volume":"62","author":"Popow","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejpb.2025.114719_b0110","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2025.114719_b0115","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2025.114719_b0120","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","article-title":"Systematic Investigation of the Permeability of Androgen Receptor PROTACs","volume":"11","author":"Scott","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2025.114719_b0125","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","article-title":"Understanding and Improving the Membrane Permeability of VH032-Based PROTACs","volume":"11","author":"Klein","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2025.114719_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105039","article-title":"BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation","volume":"138","author":"Rathod","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114719_b0135","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0140","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.3390\/molecules29174048","article-title":"Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography\u2013Tandem Mass Spectrometry","volume":"29","author":"Choi","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114719_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061977","article-title":"Development of an LC-MS\/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies","volume":"27","author":"Nguyen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114719_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112903","article-title":"First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2\/4\/6 in vivo","volume":"209","author":"Wei","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0155","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME Demonstrates ARV-110\u2019s High Druggability Despite Low Oral Bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06238-x","article-title":"Metabolism-driven in vitro\/in vivo disconnect of an oral ER\u0251 VHL-PROTAC","volume":"7","author":"Hayhow","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejpb.2025.114719_b0165","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejpb.2025.114719_b0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejpb.2019.06.011","article-title":"Evaluation of drug permeability calculation based on luminal disappearance and plasma appearance in the rat single-pass intestinal perfusion model","volume":"142","author":"Dahlgren","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116348","article-title":"Development and validation of LC-MS\/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)","volume":"249","author":"Niessen","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114719_b0185","first-page":"1939","article-title":"Improved outcome of pig islet isolation by Pefabloc inhibition of trypsin","volume":"Vol. 29, No. 4","author":"Basir","year":"1997"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114719_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0005-2760(95)00226-X","article-title":"Pefabloc, 4-[2-aminoethyl] benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase","volume":"1299","author":"Dentan","year":"1996","journal-title":"Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism"},{"key":"10.1016\/j.ejpb.2025.114719_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106076","article-title":"Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?","volume":"169","author":"Weiss","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114719_b0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp\/61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Dressman","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114719_b0205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/acs.jmedchem.1c01272","article-title":"Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations","volume":"65","author":"Urgaonkar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114719_b0210","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s11095-023-03563-4","article-title":"Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions","volume":"40","author":"Chu","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114719_b0215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0220","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional Intestinal Permeability in Rats: A Comparison of Methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0225","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejpb.2019.07.005","article-title":"Rat intestinal drug permeability: A status report and summary of repeated determinations","volume":"142","author":"Dubbelboer","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102397","article-title":"Challenges in Permeability Assessment for Oral Drug Product Development","volume":"15","author":"Koziolek","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114719_b0235","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1023\/A:1016065715308","article-title":"Comparison Between Permeability Coefficients in Rat and Human Jejunum","volume":"13","author":"Fagerholm","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114719_b0240","first-page":"1166","article-title":"Numerical convolution\/deconvolution as a tool for correlating in vitro with in vivo drug availability","volume":"44","author":"Langenbucher","year":"1982","journal-title":"Pharmazeutische Industrie"},{"key":"10.1016\/j.ejpb.2025.114719_b0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1208\/s12248-015-9849-y","article-title":"Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions","volume":"18","author":"Margolskee","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2025.114719_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-3-1","article-title":"The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption","volume":"3","author":"Levitt","year":"2003","journal-title":"BMC Clinical Pharmacology"},{"key":"10.1016\/j.ejpb.2025.114719_b0255","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/mp500834v","article-title":"Human in vivo regional intestinal permeability: Quantitation using site-specific drug absorption data","volume":"12","author":"Sj\u00f6gren","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0260","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1023\/A:1012144232666","article-title":"Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats","volume":"14","author":"Krondahl","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114719_b0265","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharmaceutical Research: an Official Journal of the American Association of Pharmaceutical Scientists"},{"key":"10.1016\/j.ejpb.2025.114719_b0270","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpt1979254408","article-title":"Kinetics and absolute bioavailability of atenolol","volume":"25","author":"Mason","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2025.114719_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/j.1552-4604.1990.tb03490.x","article-title":"Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR\/ZOK: a review article","volume":"30","author":"Sandberg","year":"1990","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114719_b0280","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/jps.23233","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: Ketoprofen","volume":"101","author":"Shohin","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114719_b0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/03602538308991383","article-title":"Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: Absorption, disposition, and metabolism in man","volume":"14","author":"Ulm","year":"1983","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejpb.2025.114719_b0290","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"de Miranda","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2025.114719_b0295","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2181922","article-title":"The emerging roles of bacterial proteases in intestinal diseases","volume":"15","author":"Caminero","year":"2023","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.ejpb.2025.114719_b0300","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.1965.tb02054.x","article-title":"The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species","volume":"25","author":"Schumacher","year":"1965","journal-title":"British journal of pharmacology and chemotherapy"},{"key":"10.1016\/j.ejpb.2025.114719_b0305","doi-asserted-by":"crossref","first-page":"26663","DOI":"10.1002\/anie.202108848","article-title":"Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs","volume":"60","author":"Min","year":"2021","journal-title":"Angewandte Chemie - International Edition"},{"key":"10.1016\/j.ejpb.2025.114719_b0310","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00003088-200443050-00004","article-title":"Clinical pharmacokinetics of thalidomide","volume":"43","author":"Teo","year":"2004","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.ejpb.2025.114719_b0315","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/js970332a","article-title":"Human intestinal permeability","volume":"87","author":"Lennern\u00e4s","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114719_b0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp0499196","article-title":"Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport","volume":"2","author":"Varma","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105850","article-title":"ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib","volume":"172","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2025.114719_b0330","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11095-006-9041-2","article-title":"Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model","volume":"23","author":"Cao","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114719_b0335","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.reprotox.2013.01.005","article-title":"Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: Implications for toxicity testing paradigms","volume":"37","author":"Kuzbari","year":"2013","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ejpb.2025.114719_b0340","first-page":"895","article-title":"Arvinas\u2019s PROTACs pass first safety and PK analysis","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2025.114719_b0345","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejpb.2021.04.005","article-title":"Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability","volume":"163","author":"Dahlgren","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114719_b0350","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1023\/A:1018965328626","article-title":"Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile","volume":"10","author":"Lennern\u00e4s","year":"1993","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:16:47Z","timestamp":1748326607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125000967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"alternative-id":["S0939641125000967"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114719","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114719"}}